Gadolinium (Gd)-DTPA-dimeglumine (tradename: Magnevist?) is the first commercially available contrast agent for magnetic resonance tomography (MRT). As a result of the very favourable results from preclinical and clinical investigations Magnevist? was granted a product license for cranial and spinal MRT in the Federal Republic of Germany in early February this year. Magnevist? is a paramagnetic...

background:  nowadays mri examinations have been widely used in clinical applications for many diagnoses. the use of contrast agent in mri improves lesion detection and characterization and causes more accurate diagnosis.  objectives: the aim of this study was comparing to optimal dose of magnevist contrast agent in modified t1w se (spin echo), t1w fse (fast spin echo) and t1w gre (gradient ech...

 Do not administer MAGNEVIST to patients with: o chronic, severe kidney disease (GFR < 30 mL/min/1.73m), or o acute kidney injury (see CONTRAINDICATIONS).  Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age >60 years, hypertension or diabetes), estimate the glomerular filtra...

background: magnetic resonance imaging (mri) is the standard method for observing brain plaques and contrast material injection is necessary for demonstrating the active plaque.this study compared the rate of enhancement of plaques with gadovist and magnevist in relapse phase of ms. methods: in this double blind study, after neurological examination of 62 patients in the attack phase of ms, two...

OBJECTIVES This study was designed to determine the enhancement profile of a necrosis-specific contrast agent (gadophrin III) in comparison to a standard extracellular agent on T1-weighted magnetic resonance (MR) images in acute and chronic myocardial infarctions (MIs). BACKGROUND Contrast-enhanced MR imaging demonstrated the ability to accurately quantify infarct size; however, some controve...

BACKGROUND Magnetic resonance imaging (MRI) is the standard method for observing brain plaques and contrast material injection is necessary for demonstrating the active plaque.This study compared the rate of enhancement of plaques with Gadovist and Magnevist in relapse phase of MS. METHODS In this double blind study, after neurological examination of 62 patients in the attack phase of MS, two...

Methods 5 control patients (4M/1F, age 44±21 y) with normal left ventricular (LV) function and no history of heart disease, 5 patients with ICM (3M/2F, 63±2 y), and 16 patients with HCM (10M/6F, age 51±15y) were recruited into an IRB approved protocol. All subjects were imaged at 1.5T (Achieva XR, Philips). T1 mapping was performed using MOLLI and LL at 2 LV short axis levels (basaland midcavit...